文献速递临床试验与 GCP

评价茯苓泽泻汤治疗无症状高尿酸血症安全性与有效性的前瞻性双盲随机安慰剂对照临床试验方案

Evaluation of the safety and efficacy of a Fuling-Zexie decoction for people with asymptomatic hyperuricemia: protocol for a prospective, double-blinded, randomized, placebo-controlled clinical trial.
PubMed 文献 · Trials · 2022-06-20

本研究为2020年3月至2021年12月开展的前瞻性双盲随机安慰剂对照预试验,计划纳入30例无症状高尿酸血症患者,中药组与安慰剂组各15例,观察12周共4次访视,主要结局为尿酸下降幅度,次要结局包括尿尿酸、炎症生物标志物等。研究旨在探讨中药治疗高尿酸血症的效果及可能机制,为后续大型临床研究提供证据。

要点

  • 计划纳入30例无症状高尿酸血症患者,中药组与安慰剂组各15例。
  • 主要结局为尿酸下降幅度,观察期12周,共4次访视。
  • 次要结局包括尿尿酸、炎症生物标志物及其他可能参与降尿酸的指标。

核心结论

  • 本研究将探讨中药治疗对高尿酸血症的效果并探索可能的治疗机制。
  • 通过开展本试验,作者希望为后续大型临床研究提供证据和数据支持。

研究设计与样本

  • 本预试验为前瞻性、双盲、随机、安慰剂对照临床试验,于2020年3月至2021年12月开展。
  • 计划招募30例无症状高尿酸血症患者,分配至中药组或安慰剂组,每组15例。
  • 观察期12周,共4次访视。

主要发现

  • 主要结局指标为尿酸下降幅度。
  • 次要结局指标包括尿尿酸、炎症生物标志物及其他可能参与降低尿酸的指标。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hyperuricemia increases the risk of gout and cardiovascular complications, and how to manage asymptomatic hyperuricemia is controversial. Randomized controlled trials and comparative studies are needed to guide management and treatment. Studies show that Chinese medicine can decrease uric acid through multiple targets, but many of these studies have been conducted in animals because of the lack of a consistent prescription and mechanism. Therefore, we designed this research to study whether Chinese medicine is truly effective and which target is essential by using an approved prescription of a Fuling-Zexie decoction to further guide large sample experiments to determine whether Chinese medicine can reduce the long-term incidence of gout and cardiovascular events. METHODS: This pilot study is a prospective, double-blinded, randomized, placebo-controlled clinical trial developed from March 2020 to December 2021. Thirty people with asymptomatic hyperuricemia will be recruited and assigned to either the Chinese medicine group or placebo group, and each group will have 15 subjects. During the 12-week observation period, there will be 4 visits. The decline in uric acid is the main outcome measure, and urinary uric acid, inflammatory biomarkers, and other indices that may be involved in lowering uric acid are the secondary outcome measures. DISCUSSION: This study will probe the effect of Chinese medicine treatment on hyperuricemia and explore possible therapeutic mechanisms. By performing this trial, we hope to provide evidence and data to support further large clinical studies. TRIAL REGISTRATION: ChiCTR2000038575 . Registered on September 24, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yan J, Zhou Y, Yang Q, et al. Evaluation of the safety and efficacy of a Fuling-Zexie decoction for people with asymptomatic hyperuricemia: protocol for a prospective, double-blinded, randomized, placebo-controlled clinical trial. Trials. 2022. PMID: 35725639. doi:10.1186/s13063-022-06479-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。